Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group directed intergroup trial S9003

Madhav V. Dhodapkar, Antje Hoering, Morie Gertz, Saul Rivkin, Jackie Szymonifka, John Crowley, Bart Barlogie

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The survival of patients with Walden- strom macroglobulinemia (WM) varies enormously. The development of prognos- tic models in WM has been fraught by limited follow-up in current studies. Here, we update the outcome of a prospective WM trial with a median follow-up of 10 years for live patients. Of the 59 previ- ously untreated patients who initially were observed, only 12 patients (21%) required therapy at a median follow-up of 100 months. Multivariate analysis among the 183 patients requiring therapy reaf- firmed age 70 years or greater, previous nonprotocol therapy, and (S-2 microglobu- lin (B2M) of 3 mg/dL or greater as prog- nostic factors. Importantly, increased se- rum lactate dehydrogenase (LDH) was identified as an additional independent variable, which improved risk assess- ment beyond the recent WM international prognostic scoring system (ISSWM). By using age, previous therapy, B2M, and LDH, we identified 3 risk groups with 8-year survival estimates of 55%, 33%, and 5% (P < .001). These data provide novel insights into factors predicting long- term outcome in WM. This trial has been registered with www.cancer.gov under ID 4852904.

Original languageEnglish (US)
Pages (from-to)793-796
Number of pages4
JournalBlood
Volume113
Issue number4
DOIs
StatePublished - Jan 22 2009

Fingerprint

Waldenstrom Macroglobulinemia
Oncology
L-Lactate Dehydrogenase
Survival
Risk assessment
Tics
Therapeutics
Multivariate Analysis
Serum
Neoplasms

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Long-term survival in Waldenstrom macroglobulinemia : 10-year follow-up of Southwest Oncology Group directed intergroup trial S9003. / Dhodapkar, Madhav V.; Hoering, Antje; Gertz, Morie; Rivkin, Saul; Szymonifka, Jackie; Crowley, John; Barlogie, Bart.

In: Blood, Vol. 113, No. 4, 22.01.2009, p. 793-796.

Research output: Contribution to journalArticle

Dhodapkar, Madhav V. ; Hoering, Antje ; Gertz, Morie ; Rivkin, Saul ; Szymonifka, Jackie ; Crowley, John ; Barlogie, Bart. / Long-term survival in Waldenstrom macroglobulinemia : 10-year follow-up of Southwest Oncology Group directed intergroup trial S9003. In: Blood. 2009 ; Vol. 113, No. 4. pp. 793-796.
@article{abd7ca7a57344cc4b31d9738b9d3de11,
title = "Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group directed intergroup trial S9003",
abstract = "The survival of patients with Walden- strom macroglobulinemia (WM) varies enormously. The development of prognos- tic models in WM has been fraught by limited follow-up in current studies. Here, we update the outcome of a prospective WM trial with a median follow-up of 10 years for live patients. Of the 59 previ- ously untreated patients who initially were observed, only 12 patients (21{\%}) required therapy at a median follow-up of 100 months. Multivariate analysis among the 183 patients requiring therapy reaf- firmed age 70 years or greater, previous nonprotocol therapy, and (S-2 microglobu- lin (B2M) of 3 mg/dL or greater as prog- nostic factors. Importantly, increased se- rum lactate dehydrogenase (LDH) was identified as an additional independent variable, which improved risk assess- ment beyond the recent WM international prognostic scoring system (ISSWM). By using age, previous therapy, B2M, and LDH, we identified 3 risk groups with 8-year survival estimates of 55{\%}, 33{\%}, and 5{\%} (P < .001). These data provide novel insights into factors predicting long- term outcome in WM. This trial has been registered with www.cancer.gov under ID 4852904.",
author = "Dhodapkar, {Madhav V.} and Antje Hoering and Morie Gertz and Saul Rivkin and Jackie Szymonifka and John Crowley and Bart Barlogie",
year = "2009",
month = "1",
day = "22",
doi = "10.1182/blood-2008-07-172080",
language = "English (US)",
volume = "113",
pages = "793--796",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Long-term survival in Waldenstrom macroglobulinemia

T2 - 10-year follow-up of Southwest Oncology Group directed intergroup trial S9003

AU - Dhodapkar, Madhav V.

AU - Hoering, Antje

AU - Gertz, Morie

AU - Rivkin, Saul

AU - Szymonifka, Jackie

AU - Crowley, John

AU - Barlogie, Bart

PY - 2009/1/22

Y1 - 2009/1/22

N2 - The survival of patients with Walden- strom macroglobulinemia (WM) varies enormously. The development of prognos- tic models in WM has been fraught by limited follow-up in current studies. Here, we update the outcome of a prospective WM trial with a median follow-up of 10 years for live patients. Of the 59 previ- ously untreated patients who initially were observed, only 12 patients (21%) required therapy at a median follow-up of 100 months. Multivariate analysis among the 183 patients requiring therapy reaf- firmed age 70 years or greater, previous nonprotocol therapy, and (S-2 microglobu- lin (B2M) of 3 mg/dL or greater as prog- nostic factors. Importantly, increased se- rum lactate dehydrogenase (LDH) was identified as an additional independent variable, which improved risk assess- ment beyond the recent WM international prognostic scoring system (ISSWM). By using age, previous therapy, B2M, and LDH, we identified 3 risk groups with 8-year survival estimates of 55%, 33%, and 5% (P < .001). These data provide novel insights into factors predicting long- term outcome in WM. This trial has been registered with www.cancer.gov under ID 4852904.

AB - The survival of patients with Walden- strom macroglobulinemia (WM) varies enormously. The development of prognos- tic models in WM has been fraught by limited follow-up in current studies. Here, we update the outcome of a prospective WM trial with a median follow-up of 10 years for live patients. Of the 59 previ- ously untreated patients who initially were observed, only 12 patients (21%) required therapy at a median follow-up of 100 months. Multivariate analysis among the 183 patients requiring therapy reaf- firmed age 70 years or greater, previous nonprotocol therapy, and (S-2 microglobu- lin (B2M) of 3 mg/dL or greater as prog- nostic factors. Importantly, increased se- rum lactate dehydrogenase (LDH) was identified as an additional independent variable, which improved risk assess- ment beyond the recent WM international prognostic scoring system (ISSWM). By using age, previous therapy, B2M, and LDH, we identified 3 risk groups with 8-year survival estimates of 55%, 33%, and 5% (P < .001). These data provide novel insights into factors predicting long- term outcome in WM. This trial has been registered with www.cancer.gov under ID 4852904.

UR - http://www.scopus.com/inward/record.url?scp=59649096871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59649096871&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-07-172080

DO - 10.1182/blood-2008-07-172080

M3 - Article

C2 - 18931340

AN - SCOPUS:59649096871

VL - 113

SP - 793

EP - 796

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -